With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the ... Although Vertex has seen solid sales growth lately, its operating margin has contracted by 1,150 bps from 51.4% in ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX ... of our Style Scores system. The proven Zacks Rank ...

their families and the healthcare system,” said Ludovic Fenaux, Senior Vice President, Vertex International. VRTX Price Action: Vertex shares were up 4.96% at $460.15 at the time of writing ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session ... these estimate changes and offers a practical rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank ...